Mark D. Faber

963 total citations
23 papers, 654 citations indexed

About

Mark D. Faber is a scholar working on Nephrology, Surgery and Epidemiology. According to data from OpenAlex, Mark D. Faber has authored 23 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Nephrology, 4 papers in Surgery and 4 papers in Epidemiology. Recurrent topics in Mark D. Faber's work include Dialysis and Renal Disease Management (11 papers), Central Venous Catheters and Hemodialysis (4 papers) and Erythropoietin and Anemia Treatment (3 papers). Mark D. Faber is often cited by papers focused on Dialysis and Renal Disease Management (11 papers), Central Venous Catheters and Hemodialysis (4 papers) and Erythropoietin and Anemia Treatment (3 papers). Mark D. Faber collaborates with scholars based in United States, Switzerland and Denmark. Mark D. Faber's co-authors include L A Liotta, Reidar Albrechtsen, Ulla M. Wewer, Carolyn M. Jagacinski, J. Frank Yates, Robert C. Basner, Thomas Röth, Edward J. Stepanski, Frank Zorick and Seth Goldberg and has published in prestigious journals such as Journal of the American Society of Nephrology, Critical Care Medicine and The American Journal of Gastroenterology.

In The Last Decade

Mark D. Faber

21 papers receiving 622 citations

Peers

Mark D. Faber

NEPHR

IMMUN

PHYSI

EPIDE

PRM

David Kershaw United States

Alexa Meara United States

Amy Law United States

Veronika Weyer Germany

Vanessa Taylor United States

Chris Wincup United Kingdom

Susan Pories United States

Silvana Di Gregorio Spain

Jessica Kubo United States

Shi‐Yang Guan China

David Kershaw United States

Mark D. Faber

548 ×2.4

NEPHR

61 ×0.5

IMMUN

27 ×0.3

PHYSI

29 ×0.4

EPIDE

53 ×0.7

PRM

Citations per year, relative to Mark D. Faber Mark D. Faber (= 1×) peers David Kershaw

Countries citing papers authored by Mark D. Faber

Since Specialization

Citations

This map shows the geographic impact of Mark D. Faber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Faber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Faber more than expected).

Fields of papers citing papers by Mark D. Faber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. Faber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Faber. The network helps show where Mark D. Faber may publish in the future.

Co-authorship network of co-authors of Mark D. Faber

This figure shows the co-authorship network connecting the top 25 collaborators of Mark D. Faber. A scholar is included among the top collaborators of Mark D. Faber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark D. Faber. Mark D. Faber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Faber, Mark D., et al.. (2022). Incremental Hemodialysis: What We Know so Far. International Journal of Nephrology and Renovascular Disease. Volume 15. 161–172. 11 indexed citations

Cruz, Cosme & Mark D. Faber. (2015). Peritoneoscopic Implantation of Catheters for Peritoneal Dialysis: Effect on Functional Survival and Incidence of Tunnel Infection. Contributions to nephrology. 89. 35–39.

Coyne, Daniel W., Seth Goldberg, Mark D. Faber, Cybele Ghossein, & Stuart M. Sprague. (2014). A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3–4 CKD. Clinical Journal of the American Society of Nephrology. 9(9). 1620–1626. 46 indexed citations

Frinak, Stanley, Gerard Zasuwa, Mark D. Faber, et al.. (2011). De novo once-monthly darbepoetin alpha treatment for the anemia of chronic kidney disease using a computerized algorithmic approach. Clinical Nephrology. 76(7). 1–8. 4 indexed citations

Russmann, Stefan, Lois Lamerato, Stephen P. Motsko, et al.. (2008). Risk of Further Decline in Renal Function After the Use of Oral Sodium Phosphate or Polyethylene Glycol in Patients With a Preexisting Glomerular Filtration Rate Below 60 ml/min. The American Journal of Gastroenterology. 103(11). 2707–2716. 24 indexed citations

Falvo, Anthony, H. Mathilda Horst, Ilan Rubinfeld, et al.. (2008). Acute renal failure in cardiothoracic surgery patients: what is the best definition of this common and potent predictor of increased morbidity and mortality. The American Journal of Surgery. 196(3). 379–383. 19 indexed citations

Brar, Indira, et al.. (2007). Reversal of Dialysis-Dependent Renal Failure in a Patient With HIV-Associated Nephropathy. Infectious Diseases in Clinical Practice. 15(6). 415–418.

Faber, Mark D.. (2006). Predicting outcomes of peritoneal-dialysis-associated peritonitis based on dialysate white blood cell count. Nature Clinical Practice Nephrology. 3(1). 14–15. 3 indexed citations

Faber, Mark D. & Jerry Yee. (2006). Diagnosis and Management of Enteric Disease and Abdominal Catastrophe in Peritoneal Dialysis Patients With Peritonitis. Advances in Chronic Kidney Disease. 13(3). 271–279. 16 indexed citations

10.

Williams, Deborah, et al.. (2003). Fivefold reduction in peritonitis using a multifaceted continuous quality initiative program.. PubMed. 19. 202–5. 24 indexed citations

11.

Shibagaki, Yugo, et al.. (2002). Feasibility of adequate solute clearance in obese patients on peritoneal dialysis: A cross-sectional study. American Journal of Kidney Diseases. 40(6). 1295–1300. 16 indexed citations

12.

Bailey, Elaine M., Mark D. Faber, & Daniel A. Nafziger. (2001). Linezolid for treatment of vancomycin-resistant enterococcal peritonitis. American Journal of Kidney Diseases. 38(4). e20.1–e20.3. 22 indexed citations

13.

Nissenson, Allen R., Mark D. Faber, D. E. Gentile, et al.. (1995). Multicenter trial of erythropoietin in patients on peritoneal dialysis.. Journal of the American Society of Nephrology. 5(7). 1517–1529. 38 indexed citations

14.

Stepanski, Edward J., Mark D. Faber, Frank Zorick, Robert C. Basner, & Thomas Röth. (1995). Sleep disorders in patients on continuous ambulatory peritoneal dialysis.. Journal of the American Society of Nephrology. 6(2). 192–197. 110 indexed citations

15.

Faber, Mark D., Robert G. Narins, & Jay H. Stein. (1992). Insidious Renal Failure. Hospital Practice. 27(5). 159–176. 1 indexed citations

16.

Faber, Mark D. & Francis Dumler. (1988). Hemodynamic Instability during Hemodialysis: An Integrated Approach. The International Journal of Artificial Organs. 11(5). 325–328. 1 indexed citations

17.

Cruz, C & Mark D. Faber. (1988). Peritoneal Catheters and Exit Site Practices. Peritoneal Dialysis International. 8(1). 57–57. 12 indexed citations

18.

Faber, Mark D., Ulla M. Wewer, Jens Berthelsen, L A Liotta, & Reidar Albrechtsen. (1986). Laminin production by human endometrial stromal cells relates to the cyclic and pathologic state of the endometrium.. PubMed Central. 124(3). 384–91. 44 indexed citations

19.

Wewer, Ulla M., Mark D. Faber, L A Liotta, & Reidar Albrechtsen. (1985). Immunochemical and ultrastructural assessment of the nature of the pericellular basement membrane of human decidual cells.. PubMed. 53(6). 624–33. 141 indexed citations

20.

Yates, J. Frank, Carolyn M. Jagacinski, & Mark D. Faber. (1978). Evaluation of partially described multiattribute options. Organizational Behavior and Human Performance. 21(2). 240–251. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact